An interventional study of Microbiota Sequencing in Crohn Disease and Spondyloarthritis, sponsored by Central Hospital, Nancy, France. Recruiting at 2 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Crohn Disease by Central Hospital, Nancy, France — 6 open to participants now, 7 under way, none of them phase 3. Crohn Disease · Central Hospital, Nancy, France.
Among the 17 studies in Crohn Disease by Central Hospital, Nancy, France, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2021, is one of 10 with no phase, and was the 6th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →6 of the 17 studies in Crohn Disease by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:
Central Hospital, Nancy, France · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18+ · Healthy volunteers
Central Hospital, Nancy, France · Sites in France
Ages 18+
Central Hospital, Nancy, France · Sites in France
Ages 18–65
Central Hospital, Nancy, France · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2021.
This study's planned enrollment of 240 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 104 across the 10 interventional studies, 60 across the 7 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Central Hospital, Nancy, France is the lead sponsor of 801 studies on the registry; 188 are open to participants now.
3 of the studies in Crohn Disease by Central Hospital, Nancy, France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05254886Central Hospital, Nancy, FranceIdentification and Management of Comorbidities and Extra-intestinal Manifestations in Crohn's Disease: the NEMO Nurse-led Program | 2027-01-01 |
| NCT07413653Central Hospital, Nancy, FranceVirtual hIStology of Crohn's Disease Ex-vivo Resected Anatomical Lesions | 2027-10-01 |
| NCT03983473Central Hospital, Nancy, FranceIdentification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease. | 2027-11-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Crohn Disease by Central Hospital, Nancy, France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The MICROSPA project aims to compare gut microbiota, serum cytokines, and PBMC of patients suffering from Crohn's disease (CD) associated or not to spondylarthritis (SpA). 3 groups of patients will be analyzed: patients suffering from CD alone, patients suffering from SpA alone, patients suffering from CD and SpA. One group of healthy controls will be analysed as a comparator. Fecal microbiota will be determined by bacteriome, virome and fungome NGS sequencing
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients suffering from established Crohn 's disease without spondyloarthritis
Other: Microbiota Sequencing
Patients with established spondyloarthritis without Crohn 's disease
Other: Microbiota Sequencing
Patients suffering from both spondyloarthritis and Crohn 's disease
Other: Microbiota Sequencing
Patients without spondyloarthritis and Crohn 's disease
Other: Microbiota Sequencing
virome, bacteriome, fungome NGS sequencing
Alpha and Beta diversity of Fecal bacteriome
Alpha (number of species) and Beta diversity (distribution of species)
Time frame: + 6 months
Alpha and Beta diversity of Fecal fungome
Alpha (number of species) and Beta diversity (distribution of species)
Time frame: + 6 months
Alpha and Beta diversity of Fecal virome
Alpha (number of species) and Beta diversity (distribution of species)
Time frame: + 6 months
Started Nov 2021 (actual). Primary completion is estimated for Nov 2027, 71 months after the start.
Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 71 months is above that.
Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital, Nancy, France →